Artigo de peri??dico
Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity
Registro en:
0969-8051
49
10.1016/j.nucmedbio.2017.03.002
53.101
Autor
SEO, DANIELE
FAINTUCH, BLUMA L.
OLIVEIRA, ERICA A. de
FAINTUCH, JOEL
Resumen
Introduction: Radiolabeled GLP-1 and its analog Exendin-4, have been employed in diabetes and insulinoma.
No protocol in conventional Diet-Induced Obesity (DIO), and Diet-Restricted Obesity (DRO), has been identified.
Aiming to assess pancreatic beta cell uptake in DIO and DRO, a protocol was designed.
Methods: GLP-1-??Ala-HYNIC and HYNIC-??Ala-Exendin-4 were labeled with technetium-99m. Four Swiss mouse
models were adopted: Controls (C), Alloxan Diabetes Controls (ADC), DIO and DRO. Biodistribution and ex-vivo
planar imaging were documented.
Results: Radiolabeling yield was in the range of 97% and both agents were hydrophilic. Fasting Blood Glucose
(FBG) was 79.2 ?? 8.2 mg/dl in C, 590.4 ?? 23.3 mg/dl in ADC, 234.3 ?? 66.7 mg/dl in DIO, and 96.6 ?? 9.3
in DRO (p = 0.010). Biodistribution confirmed predominantly urinary excretion. DIO mice exhibited
depressed uptake in liver and pancreas, for both radiomarkers, in the range of ADC. DRO only partially restored
such values. 99mTc-HYNIC-??Ala-Exendin-4 demonstrated better results than GLP-1-??Ala-HYNIC-99mTc.
Conclusions: 1) Diet-induced obesity remarkably depressed beta cell uptake; 2) Restriction of obesity failed to
normalize uptake, despite robust improvement of FBG; 3) HYNIC-??Ala-Exendin-4 was the most useful marker;
4) Further studies are recommended in obesity and dieting, including bariatric surgery.